Key facts
- It has raised $1.0M across 3 recorded rounds; the latest was Seed Round ($320K) in Jan 2026.
- Omega Ophthalmics has filed 2 Form Ds with the SEC since 2022, most recently Jan 2025 ($250K sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·Watchlist + deal alerts for Omega Ophthalmics
Funding rounds
3 roundsAbout Omega Ophthalmics
Developer of surgically implanted lenses designed to create a space for augmented reality inside the eye. The company offers proprietary technologies for intraocular lenses, capsular bags, and high-technology applications within the eye, enabling surgeons to increase the number of glasses-free post-surgery patients by reducing the variables during surgery.
- Sector
- Healthcare
- HQ
- Lexington, KY, United States
- Founded
- 2012
- Website
- omegaophthalmics.com/
- Ownership
- Privately Held (backing)
Omega Ophthalmics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Omega Ophthalmics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Omega Ophthalmics in its N-PORT filings yet. We sweep new filings monthly.